Stock·NASDAQ·Healthcare
Regeneron Pharmaceuticals, Inc. (REGN)
- Market cap
- $81.41B
- P/E
- 19.69
- Dividend yield
- 0.47%
- Street target
- $857.00median of 27 analysts
- 52-week range
- $572.75 $859.34
The short version
Where REGN stands today, in four lines, and what CleaRank Financial AI makes of it.
REGN at a glance
Regeneron Pharmaceuticals, Inc. (REGN): Buy, 74/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($735.42 and $790.85).
- Earnings REGN beat estimates in 6 of its last 7 quarters, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $12.9M and made no open-market purchases over the last 18 months.
- Valuation P/E of 19.7 against 31.9 for the Healthcare sector: a discount to peers (-38%).
Figures as of October 18, 2026.
CleaRank Financial AI
CleaRank rates Regeneron Pharmaceuticals, Inc. (REGN) a Buy with a model score of 74/100.
The strongest contributor is the trend: the price is 7.52% above its 200-day average, and the 50-day average is 7.54% above the 200-day. The MACD line is negative, which makes momentum the weakest contributor. The 50-day average is $790.85 and the 200-day average is $735.42. The price rose 38.93% over the past year.
Only on CleaRank
Figures we compute ourselves from REGN's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $790.74 is 0.0% below the 50-day simple moving average of $790.85.Price above its 200-day average ›
The price is 7.5% above the 200-day simple moving average of $735.42.50-day average above the 200-day ›
The 50-day average ($790.85) is 7.5% above the 200-day average ($735.42), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 76% of its 52-week range, between $572.75 and $859.34.
REGN share price
Pick a period: each tab shows how far REGN has moved over it, to the last close.
Today's trading
Where REGN sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 19.69 is 38.3% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 5.28 is 55.2% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $4.3B on revenue of $15.5B, a net margin of 27.9%.Beat estimates in most recent reports ›
REGN beat the EPS estimate in 6 of its last 7 reports.Pays a dividend ›
The trailing dividend yield is 0.47%, or $3.70 a share a year.
Key statistics
The headline figures for REGN.
As of October 18, 2026, REGN trades at $790.74, with a market value of $81.41B, a P/E ratio of 19.69 and a dividend yield of 0.47%.
What the numbers say
CleaRank Financial AI's reading of REGN's valuation, growth and risks.
Regeneron Pharmaceuticals, Inc. (REGN) has a trailing P/E of 19.69, which is 38.3% below the Healthcare median of 31.9. The peer comparison on this page rates the P/E as a discount to peers. Measured on sales, the price-to-sales ratio of 5.28 is 55.3% above the sector median of 3.4. Its market capitalisation stands at $81.4B.
REGN is growing faster than its sector. Revenue rose 16.70% in the latest year, while the sector median is 8.1%. The company keeps a net margin of 27.87% and an operating margin of 33.11%, and its return on equity of 14.04% is above the sector median of 7.3%. On the balance sheet, debt-to-equity stands at 0.09, and the trailing dividend yield is 0.47%, or $3.70 a share a year.
REGN's latest report, released on July 30, 2026, beat the estimate by 39.96%: earnings came in at $14.29 a share versus a $10.21 forecast. Investors responded positively, and the stock rose 3.29% in the next session.
REGN has topped the EPS estimate in 6 of its last 7 reports, yet the stock still dropped in the first session after 1 of those 6 beats. Analysts expect EPS of $55.95 for this fiscal year and $50.63 for next year, with the current year showing growth of 26.3%.
REGN's average daily move is 1.73%. Over the last 18 months insiders sold $12.9M of stock and made no open-market purchases. Insider sales are often planned in advance or made to cover taxes on vesting shares, so they carry less weight than purchases would.
REGN against the Healthcare sector
How REGN compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: REGN trades at a notable discount to sector peers (-38%), which may indicate undervaluation or specific company headwinds.
Return vs XLV: Since May 6, 2025, REGN has gained 41.6% against a gain of 31.6% for XLV.
Performance against XLV
REGN and the Healthcare sector fund over the same days.
Revenue and earnings
How much REGN sells, and how much of it becomes profit.
Revenue growth: Revenue grew 1.0% in FY2025 to $14.3B, from $14.2B a year earlier.
Profit margin: The net margin was 31.4% in FY2025, up from 31.1% the year before.
Profitable: REGN earned $4.5B in FY2025.
Earnings reality check
Did REGN beat what analysts expected, and how did the stock react?
Earnings record: REGN beat the analyst estimate in 6 of the last 7 quarters.
Market reaction: The stock fell in the first session after 1 of those 6 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 30, 2026after close | $10.21 | $14.29 | +39.96% | +3.29% | +4.57% |
| Apr 29, 2026after close | $8.90 | $9.47 | +6.40% | +3.02% | +5.05% |
| Oct 28, 2025after close | $9.64 | $11.83 | +22.72% | -0.24% | -4.05% |
| Aug 1, 2025after close | $8.44 | $12.89 | +52.73% | +2.27% | +0.74% |
| Apr 29, 2025after close | $8.48 | $8.22 | -3.07% | +5.25% | -1.83% |
| Feb 4, 2025after close | $11.19 | $12.07 | +7.86% | +2.82% | -4.53% |
| Oct 31, 2024after close | $11.70 | $12.46 | +6.50% | +0.64% | -1.64% |
As of October 18, 2026, REGN has beaten the analyst EPS estimate in 6 of its last 7 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on July 30, 2026, came in 39.96% above the estimate and the stock moved +3.29% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 57.2, in neutral territory.RSI above 50 ›
An RSI of 57.2 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of REGN
The score, the reasoning behind it, and what could move the price next.
Regeneron Pharmaceuticals, Inc. (REGN) sends a mixed trend signal: at $790.74, it trades 0.01% below its 50-day average of $790.85 but 7.52% above its 200-day average of $735.42. The price sits near the top of its 52-week range, 7.98% below the high of $859.34 and 38.06% above the low of $572.75. With the 50-day average 7.54% above the 200-day, the averages have not yet caught up with the weaker price.
Every period shown points up for REGN. Over the past three months the price rose 16.85%, over the past six months it rose 5.35%, and over the past year it rose 38.93%. Momentum is more mixed: the 14-day RSI of 57.2 sits in the neutral zone, and the MACD line is negative.
Earnings beat ›
The July 30, 2026 report beat the EPS estimate by 39.96%, and the share price rose 3.29% in the first session after it.
Source: Earnings report, July 30, 2026Analyst upgrade ›
Argus Research upgraded it to Buy from Hold on October 1, 2026.
Source: Analyst action, Argus Research, October 1, 2026
Rating reaffirmed ›
RBC Capital kept its Sector Perform rating on October 8, 2026.
Source: Analyst action, RBC Capital, October 8, 2026
- Two levels matter most right now: the 52-week high at $859.34 above the price, and the 20-day EMA at $768.25 below it.
- The 14-day RSI reads 57.2, which is neutral, and the MACD line is negative. Readings above 70 or below 30 would point to stretched momentum.
- Following the July 30, 2026 report, the share price climbed 3.29% in the first session. Across the last 7 reports, REGN beat estimates in 6 of them.
REGN is trading right at the 50-day SMA. The trend is mixed: REGN is above its 200-day average at $735.42 but below its 50-day average at $790.85. A close above the 50-day would turn both signals up, and a close below the 200-day would turn both down. The next levels are the 20-day EMA at $768.25 below and the 52-week high at $859.34 above.
With a 14-day RSI of 57.2, REGN sits in neutral territory, between 40 and 60.
Technical indicators
Momentum and trend for REGN, from its daily closes.
As of October 18, 2026, with REGN at $790.74, its 14-day RSI is 57.2 (neutral territory), its 50-day simple moving average is $790.85 and its 200-day is $735.42.
Calculated by CleaRank on daily closes as of October 18, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What REGN moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 18, 2026, REGN's 1-year correlation of daily returns is +0.28 with S&P 500 (SPY), +0.20 with Nasdaq 100 (QQQ), +0.08 with Bitcoin (BTC) and +0.09 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
18 of 27 analysts rate it a buy or strong buy, 8 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $857.00 is 8.4% above the price.More buy ratings than three months ago ›
18 of 27 rate it a buy now, against 18 of 28 three months ago.
REGN Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Maintains | Sector Perform |
| Oct 7, 2026 | Truist Securities | Maintains | Buy |
| Oct 7, 2026 | Morgan Stanley | Maintains | Equal-Weight |
| Oct 6, 2026 | JP Morgan | Maintains | Overweight |
| Oct 1, 2026 | Jefferies | Maintains | Buy |
| Oct 1, 2026 | Argus Research | Upgrade | Buy |
As of October 18, 2026, 27 Wall Street analysts cover REGN: 18 rate it a buy or strong buy, 8 a hold and 1 a sell or strong sell. Their 12-month price targets range from $730.00 to $1,030.00, with a median of $857.00, 8.4% above the price of $790.74.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
REGN trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from REGN's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much REGN tends to move, against the market and on its own.
The long record
REGN's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 1.73% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 59.0%, from August 2024 to May 2025; the price is still 33.4% below that peak.Most 1-year holds ended higher ›
64% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $21,484, against $41,793 in the S&P 500 (SPY).
REGN Drawdowns & Recovery
As of October 18, 2026, REGN's worst peak-to-trough fall over the last 10 years with dividends reinvested was -59.0% (August 2024 to May 2025); it is still 33.4% below that peak, and 64% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into REGN in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: REGN trailed the S&P 500 over this period: $21,484 against $41,793.
A $10,000 investment in REGN in October 2016 would be worth about $21,484 today with dividends reinvested, compared with about $41,793 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to REGN, and which have not.
Strongest month, August: an average of +6.15%, up in 7 of 10 years.
Weakest month, September: an average of -4.03%, up in 2 of 10 years.
This month, October: has averaged -1.36%, up in 3 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, REGN's strongest calendar month has been August (average +6.15%, up in 7 of 10 years) and its weakest September (average -4.03%, up in 2 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in REGN, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in REGN today could grow to about $19,564 by 2036 in the base case, with a 90th-percentile outcome near $71,964 and a 10th-percentile outcome around $5,318. The simulation models price only; at today's 0.47% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
REGN Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $1,034 for REGN by 2030 in the base case, from $791 today (1.3x over 4 years). The 10th-percentile path ends near $454. These are outcomes of a Monte Carlo simulation run on REGN's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $560 | $846 | $1,277 | |
| 2028 | $505 | $904 | $1,619 | |
| 2029 | $474 | $967 | $1,974 | |
| 2030 | $454 | $1,034 | $2,357 | |
| 2031 | $440 | $1,106 | $2,778 |
Method: a lognormal simulation of REGN's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
REGN insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought REGN shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 18, 2026, REGN insiders reported 15 open-market sales worth $12.9M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 3, 2026 | Marion E Mccourt
Officer
|
Sell | 2.3K | $2.0M |
| Sep 2, 2026 | Kathryn Ph.d. Guarini
Director
|
Sell | 400 | $340.0K |
| Sep 2, 2026 | Kathryn Ph.d. Guarini
Director
|
Option | 400 | $287.7K |
| Aug 19, 2026 | Joseph J Larosa
General Counsel
|
Option | 12.3K | $4.7M |
| Aug 18, 2026 | Christopher R Fenimore
Chief Financial Officer
|
Option | 6.3K | $2.4M |
| Aug 10, 2026 | Huda Y Zoghbi
Director
|
Sell | 800 | $640.0K |
| Aug 10, 2026 | Kathryn Ph.d. Guarini
Director
|
Sell | 400 | $320.0K |
| Aug 10, 2026 | Kathryn Ph.d. Guarini
Director
|
Option | 400 | $287.7K |
| Aug 10, 2026 | Huda Y Zoghbi
Director
|
Option | 800 | $301.4K |
| Jul 2, 2026 | Arthur F. Ryan
Director
|
Sell | 200 | $130.0K |
| May 1, 2026 | Arthur F. Ryan
Director
|
Sell | 100 | $70.5K |
| Apr 1, 2026 | Arthur F. Ryan
Director
|
Sell | 100 | $77.7K |
| Mar 2, 2026 | Arthur F. Ryan
Director
|
Sell | 100 | $78.6K |
| Feb 19, 2026 | Huda Y Zoghbi
Director
|
Sell | 1.6K | $1.3M |
| Feb 19, 2026 | Huda Y Zoghbi
Director
|
Option | 1.6K | $617.0K |
| Feb 9, 2026 | Jason Pitofsky
Officer
|
Sell | 2.0K | $1.6M |
| Feb 9, 2026 | Arthur F. Ryan
Director
|
Sell | 100 | $77.9K |
| Feb 9, 2026 | Jason Pitofsky
Officer
|
Option | 1.0K | $492.0K |
| Jan 7, 2026 | Bonnie L Bassler
Director
|
Sell | 1.5K | $1.2M |
| Jan 7, 2026 | Bonnie L Bassler
Director
|
Option | 1.5K | $561.2K |
| Jan 2, 2026 | Bonnie L Bassler
Director
|
Grant | 155 | - |
| Jan 2, 2026 | Michael S Brown
Director
|
Grant | 155 | - |
| Jan 2, 2026 | Neavelle Anthony Coles
Director
|
Grant | 155 | - |
| Jan 2, 2026 | Joseph L Goldstein
Director
|
Grant | 155 | - |
| Jan 2, 2026 | Kathryn Ph.d. Guarini
Director
|
Grant | 155 | - |
| Jan 2, 2026 | Christine A Poon
Director
|
Grant | 155 | - |
| Jan 2, 2026 | David P Schenkein
Director
|
Grant | 155 | - |
| Jan 2, 2026 | George Louis Sing
Director
|
Grant | 155 | - |
| Jan 2, 2026 | Craig B Thompson
Director
|
Grant | 155 | - |
| Jan 2, 2026 | Huda Y Zoghbi
Director
|
Grant | 155 | - |
| Dec 31, 2025 | Leonard S Schleifer
Chief Executive Officer
|
Grant | 28.6K | - |
| Dec 31, 2025 | George D Yancopoulos
President
|
Grant | 28.6K | - |
| Dec 30, 2025 | George Louis Sing
Director
|
Option | 9.2K | $4.8M |
| Dec 9, 2025 | Leonard S Schleifer
Chief Executive Officer
|
Option | 172.7K | $96.0M |
| Dec 9, 2025 | George D Yancopoulos
President
|
Option | 146.8K | $81.6M |
| Dec 5, 2025 | Christopher R Fenimore
Chief Financial Officer
|
Grant | 3.0K | - |
| Dec 5, 2025 | Joseph J Larosa
General Counsel
|
Grant | 2.5K | - |
| Dec 5, 2025 | Marion E Mccourt
Officer
|
Grant | 2.5K | - |
| Dec 5, 2025 | Andrew J Murphy
Officer
|
Grant | 3.7K | - |
| Dec 5, 2025 | Jason Pitofsky
Officer
|
Grant | 2.1K | - |
| Dec 5, 2025 | Plew Daniel P Van
Officer
|
Grant | 3.7K | - |
| Nov 20, 2025 | Bonnie L Bassler
Director
|
Sell | 760 | $570.0K |
| Nov 20, 2025 | Bonnie L Bassler
Director
|
Option | 760 | $282.3K |
| Nov 20, 2025 | Joseph J Larosa
General Counsel
|
Option | 14.5K | $8.0M |
| Nov 7, 2025 | Jason Pitofsky
Officer
|
Sell | 431 | $280.8K |
| Oct 30, 2025 | Andrew J Murphy
Officer
|
Grant | 1.5K | - |
| Oct 30, 2025 | Christine A Poon
Director
|
Option | 9.2K | $4.8M |
| Oct 29, 2025 | Christine A Poon
Director
|
Sell | 6.5K | $4.3M |
| Oct 29, 2025 | Andrew J Murphy
Officer
|
Option | 35.0K | $19.4M |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 18, 2026.